Tiziana Life Sciences LTD
14
4
4
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
42.9%
6 terminated/withdrawn out of 14 trials
25.0%
-61.5% vs industry average
0%
0 trials in Phase 3/4
100%
2 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
Role: collaborator
A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients
Role: lead
A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)
Role: lead
Intermediate-Size Patient Population Expanded Access: Foralumab in Non-Active Secondary Progressive MS Patients
Role: lead
Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis
Role: lead
Safety, Tolerability and Immune Effects of the Nasal Foralumab in Healthy Human Volunteers
Role: lead
Milciclib in Combination With Gemcitabine in Advanced NSCLC
Role: lead
A Study of Oral Foralumab in Participants With Moderate to Severely Active Crohn's Disease
Role: lead
In-patient COVID-19 Study of Intranasal Foralumab
Role: lead
Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS
Role: lead
Study of Milciclib in Patients With Unresectable/Metastatic Hepatocellular Carcinoma
Role: lead
Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DM
Role: lead
Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy
Role: lead
Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma
Role: lead
All 14 trials loaded